Neuralink Says 12 People Have Received Its Brain Implants, Raising Hope and Questions About Safety and Access
Neuralink says 12 people have received its brain implants and are actively using them in the PRIME clinical trial, controlling digital devices by thought — a major step toward restoring autonomy for people with spinal cord injuries or ALS.
Key takeaways
- 12 patients: Neuralink reports 12 people have received and used its N1 “Telepathy” device in the PRIME human trial (Neuralink confirms 12 patients have used the device).
- How it works: Microscopic threads and robot-assisted surgery read cortex signals and decode them to control cursors, phones and software (NPR Illinois primer; Observer).
- Benefits and limits: Users have achieved tasks like cursor control and messaging with high accuracy for some tasks, but precise hand-like movements and long-term data remain limited (CGTN).
- Safety and ethics: Animal-testing controversies, surgical revisions and long-term risks underline the need for transparent data and regulatory oversight (EM360Tech).
Overview
Neuralink announced that 12 individuals have received and are using its neural interface chips as part of the PRIME clinical trial. The company describes this as tangible progress toward practical brain-computer interface (BCI) devices that can restore digital autonomy for people with severe paralysis (Neuralink confirms 12 patients have used the device).
The device and how surgery is done
The implant is identified as the N1 or “Telepathy” device; Neuralink places it with a robot-assisted procedure. The company says hair-thin threads read neural signals and the device’s software decodes brain activity into commands for cursors, phones and apps (Observer; EM360Tech).
Technical details reported elsewhere note the threads are microscopic — roughly 10–12 microns — and are placed to limit insertion injury. A robotic inserter aims for precise placement and the system relies on downstream decoding algorithms to translate measured neural patterns into digital commands (NPR Illinois).
Who is enrolled and what recipients can do
Participants are adults (22+) with quadriplegia from spinal cord injury or ALS enrolled in the PRIME — Precise Robotically Implanted Brain-Computer Interface — study. The trial’s stated aim is to restore digital autonomy and ultimately help restore movement (NPR Illinois).
Early, public recipients — notably Noland Arbaugh in demonstrations — have used the implant to move a cursor, play chess and perform tasks such as browsing the web, sending emails and using professional design software through thought-driven controls (Observer; CGTN).
Clinical trial details and locations
The PRIME study is the central human safety and function trial for Neuralink’s device. Day-to-day testing and monitoring have been reported at centers including Barrow Neurological Institute, where several participants took part in study activities and follow-up evaluations (CGTN).
Performance, revisions and technical challenges
Neuralink reports high accuracy for some decoding tasks — users have achieved up to ≈90% accuracy when controlling a cursor for certain tasks — but the system still lags for fine, hand-like movements and broader device compatibility (CGTN).
After early reports of loose threads and retraction, Neuralink says it adjusted surgical technique and now places threads deeper while refining approaches to limit brain motion and retraction events (Observer).
Safety, ethics and controversy
Scrutiny persists. Critics point to animal testing outcomes that reportedly led to deaths and raised ethical questions, prompting public debate and regulatory attention as human trials proceed (EM360Tech).
All invasive brain implants carry risks — infection, bleeding, device failure and unknown long-term complications — and ethics boards and regulators are monitoring trials like PRIME to weigh benefits versus harms (NPR Illinois).
Public demonstrations and user stories
Public demos of early recipients show practical capabilities: Noland Arbaugh moved a cursor and played chess in early demonstrations, illustrating proof of concept for basic digital tasks (Observer).
Other participants reportedly used the system for web browsing, messaging and professional software tasks, suggesting potential daily-life benefits for people with severe mobility limits (CGTN).
Company goals and near-term outlook
Neuralink has stated an expectation of 20–30 implants in the year while iterating on hardware and software to improve reliability and expand capability (Observer).
The company continues refining implantation, thread placement and signal decoding as the PRIME study collects additional performance and safety data (Observer; CGTN).
Investigative perspective: what remains unclear
Independent long-term outcome data remain limited. Public announcements and case examples are encouraging but do not yet substitute for full trial datasets and peer-reviewed publications. Key unknowns include device durability, long-term infection rates, upgrade/removal strategies and transparent regulatory filings.
Implications for Sonoma, California
Healthcare access: Sonoma County’s hospitals and rehab centers could see increased interest if BCI trials expand in the Bay Area, creating demand for coordination, travel support and local follow-up care.
Local economy and workforce: Advances in BCI may spur partnerships, clinical jobs and new services for therapists, nurses and device technicians — and open opportunities for startups focused on rehabilitation tools and BCI-compatible software.
Ethical and regulatory conversation: Community forums, patient-advocacy organizations and policymakers should expect debates over safety, privacy, consent and equitable access as implants become more common.
Care and preparedness: Caregivers will need training on device maintenance and complication recognition; local clinicians and public health officials should coordinate with Bay Area centers to plan follow-up and emergency responses.
Substantive reporting and next steps
Journalists and local leaders are advised to seek independent trial data, peer-reviewed results and ethics board statements as Neuralink reports more outcomes. For residents with paralysis or ALS, advances bring hope but underscore the need for clear, evidence-based information about benefits and risks.
Source list for reported facts
- TechSpot: Neuralink confirms 12 patients have used the device
- Observer: Details on the N1 “Telepathy” device, early patients and company goals
- CGTN: Reports on patient use, accuracy and Barrow Neurological Institute participation
- EM360Tech: Overview and ethical concerns including animal testing controversy
- NPR Illinois: Background on PRIME trial, target population and implant thread size
Reporting by Times Media Service
